GESELLSCHAFT FÜR THROMBOSE- UND HÄMOSTASEFORSCHU..
69th GTH Annual Meeting 202518-21 February 2025 Lausanne
N. Poster
Poster title
Applicant name
Status
 |
|
|
|
| 1-PW | Rapid resolution of factor VIII inhibitor with combination therapy with Rituximab and steroids | Sabina Dhami |  Received |
 |
|||
| 1-PW | Gabapentin and pregabalin can be associated with clinically relevant bleeding due to disturbed platelet function Two case reports | Beate E. Kehrel | Received |
|
|||
| 2-PW | Interim Results on the Impact of Rivaroxaban Dose Escalation on Recanalisation Time in Paediatric Patients with Venous Thromboembolism | Susan Halimeh | Received |
|
|||
| 2-PW | Plasma levels and Reversal strategies in 100 consecutive DOAC emergencies - a single center case series | Luise Tittl | Received |
|
|||
| 2-PW | Advancing Treatment Options: Two Phase 3 Studies Investigating the Efficacy, Safety, and Pharmacokinetics of an Antithrombin Concentrate in Patients with Congenital and Acquired Antithrombin Deficiency | Cristina Solomon | Received |
|
|||
| 2-PW | Compassionate use of osocimab in preventing thrombotic complications without incremental bleeding: a case report | Jan Beyer-Westendorf | Received |
|
|||
| 2-PW | Use of DOAC Dipstick point-of-care testing in patients with acute stroke and transient ischemic attack | Maximilian Ziegler | Received |
|
|||
| 2-PW | A patient with Klippel-Trénaunay-Syndrom and cerebral venous sinus thrombosis | Carolin Wartenberg | Received |
|
|||
| 4-PW | Severe autoimmune Heparin Induced Thrombocytopenia with persistence over years: a case report | Thomas Lecompte | Received |
|
|||
| 7-PW | Damoctocog Alfa Pegol in German Patients With Severe and Non-Severe Haemophilia A: Fifth Interim Analysis of the Real-World HEM-POWR Study | Amanda Ward | Received |
|
|||
| 7-PW | The Great Return: Rebuilding and Advancing the Swiss Haemophilia Registry | Alessandra Bosch | Received |
|
|||
| 7-PW | Interim Analysis of Joint Outcomes in Adult and Adolescent Patients with Severe Hemophilia A Receiving Efanesoctocog Alfa During the Phase 3 XTEND-ed Long-Term Extension Study | Elisabeth Bauer | Received |
|
|||
| 7-PW | Efanesoctocog alfa treatment outcomes in subjects =50 years of age from the XTEND-1 trial | Elisabeth Bauer | Received |
|
|||
| 7-PW | Perioperative Management with Efanesoctocog Alfa in Adults, Adolescents, and Children with Severe Hemophilia A in the Phase 3 XTEND Clinical Program | Elisabeth Bauer | Received |
|
|||
| 7-PW | Health-related quality-of-life outcomes 4 years after treatment with valoctocogene roxaparvovec | Gillian Clague | Received |
|
|||
| 7-PW | Efficacy and safety of valoctocogene roxaparvovec 4 years after gene transfer in GENEr8-1 | Gillian Clague | Received |
|
|||
| 7-PW | Valoctocogene roxaparvovec estimated long-term durability of treatment effect: An extrapolation of the most recent clinical data | Gillian Clague | Received |
|
|||
| 7-PW | Evaluation of Pharmacokinetics, Efficacy and Safety of a New Human Fibrinogen Concentrate in Patients with Congenital Fibrinogen Deficiency | Thorsten Einhaeuser | Received |
|
|||
| 7-PW | Pregnancy complications in female haemophilia patients and carriers of haemophilia A and B- a nationwide survey | Rosa Sonja Alesci | Received |
|
|||
| 7-PW | Feasibility of tests for sports motor skills (general fitness, proprioception and balance) in patients with hemophilia and association with pain and orthopedic joint status | Katharina Holstein | Received |
|
|||
| 7-PW | Real-World Effectiveness and Usage of Recombinant Factor IX Fc: Interim Analysis in Paediatric Patients from the 24-Month, Prospective, Non-Interventional B-MORE Study | Elisabeth Bauer | Received |
|
|||
| 7-PW | Third Interim Analysis from B-MORE: A 24-Month Prospective, Multicentre, Non-Interventional Study on the Real-Word Effectiveness and Usage of Recombinant Factor IX Fc (rFIXFc) in Haemophilia B | Elisabeth Bauer | Received |
|
|||
| 9-PW | Development and evaluation of a novel machine learning algorithm for outpatient thrombophilia diagnosis, management, and venous thrombosis risk stratification | Hannah McRae | Received |
|
|||
| 9-PW | Promoting young talents - Coagulation for bloody beginners (Gerinnung für blutige Anfänger*innen) | Kai Severin | Received |
|
|||
| 9-PW | Aspects of long-term joint health in haemophilia A: inSight Joint Health tool | Anke Tripp Dr | Received |
|
|||
| 9-PW | Efficacy and safety of Mim8 prophylaxis in adults and adolescents with hemophilia A with or without inhibitors: Phase 3, open-label, randomized, controlled FRONTIER2 study | Johannes Oldenburg | Received |
|
|||
| 9-PW | Bridging Language Barriers in Hemophilia Care with a Digital Translation Tool | Alexander Stavrev | Received |
|
|||
| 10-PW | Massive portal vein thrombosis due to platelet-activating PF4 antibodies without proximate heparin exposure, infection, or SARS-CoV-2 vaccination | Florian Langer | Received |
|
|||
| 13-PW | Comparison of thrombin biomarkers and activated protein C in patients with cerebral venous sinus thrombosis and splanchnic vein thrombosis | Heiko Rühl | Received |
|
|||
| 13-PW | Assessing the impact of a pulmonary embolism response team on patients presenting with pulmonary embolism | Wei Liang Tan | Received |
|
|||
| 14-PW | Paving the way to assay automation: Improving and simplifying VWF activity determination of VWF concentrates | Gerald Schrenk | Received |
|
|||
| 14-PW | Novel heterozygous termination variants causing von Willebrand disease type 1 | Carmen Klepka | Received |
|
|||
| 14-PW | Clinical Response and Refractoriness in Immune Thrombotic Thrombocytopenic Pupura | Lucas Kühne | Received |
|
|||
| 15-PW | Effectiveness of emicizumab under real-world conditions in patients of all ages with hemophilia A with and without FVIII inhibitors: Third interim analysis of the non-interventional study EMIIL | Petra Joestingmeyer | Received |
|
|||
69th GTH Annual Meeting 2025
18-21 February 2025 Lausanne
Search and consult posters online
in an exclusive section
for each poster
in an exclusive section
for each poster
ACTIVE FROM 18/02/2025 TO 18/02/2025
Poster
Gallery
Gallery
Upload
Poster
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
Forum
|
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.
|
|
||
|
||||
|
|
